Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 140,660
- 试验地点
- 2
- 主要终点
- Hospital Admissions.
研究概览
简要总结
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
详细描述
BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but none died nor hospitalized after receiving early treatment with antihistamines. Other case reports have suggested a protective role of amantadine, since infected patients showed a very mild COVID19 infection.
OBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of COVID19.
METHODS. Describe the rate of hospitalization, ICU, survival, postcovid syndrome and thrombosis among COVID 19 cases having antihistamines and amantadine as chronic treatments.
The rates would be stratified by age groups and compared with the same age groups of the population assigned to the public free Access Terrassa Health Consortium.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients having chronic treatment with antihistamines or amantadine -
排除标准
- 未提供
研究组 & 干预措施
Other population of the THC
The % of patients of the Terrassa Health Consortium that suffered COVID19 infection of the same age groups.
Patients with chronic treatment with antihistamines or amantadine
The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups.
干预措施: Amantadine (Drug)
Patients with chronic treatment with antihistamines or amantadine
The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups.
干预措施: Antihistamine (Drug)
结局指标
主要结局
Hospital Admissions.
时间窗: from march 2020.
Rate of Hospitalization among COVID 19 infections
次要结局
- Survival(from march 2020)
- Symptomatic infection(from march 2020)
- Postcovid syndrome(from april 2020)
- Thrombosis(from april 2020)
研究者
Anna Puigdellívol-Sánchez
Principal Investigator
Consorci Sanitari de Terrassa